Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised,…

By O. Rascol, D. Brooks, E. Melamed, W. Oertel, W. Poewe, F. Stocchi, Eduardo Tolosa. The Lancet, 2005

598 citations recorded by the source corpus.

Subfields: Neurology

View Paper: https://www.semanticscholar.org/paper/4fafa4195e9e6aaebba1d311706a3eb3b18e44e4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Seppi
2. M. Coelho
3. S. Fox
4. R. Katzenschlager
5. C. Sampaio
6. D. Edmondson
7. Shen-Yang Lim
8. K. Tipton

Citations in the corpus

• The therapeutic potential of monoamine oxidase inhibitors (2006, background): “More recent evidence suggests that rasagiline and lazabemide can also delay the progression of the disabilities associated with Parkinson's diseas”
• International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease (2018, result): “A study previously discussed in the 2011 EBM review(9) found comparable effects of entacapone and rasagiline in reducing OFF time.(171) Mixed MAO-B inhibition with glutamate release inhibition using the new agent safinamide is “clinically useful.”